Median DOR of 21.7 months with 80% of responders achieving a deep response (≥80% tumor shrinkage) Depth and durability translating to prolonged OS with median OS of 21.3 months and 2-year OS of 46% in ...

Vepdegestrant, an investigational estrogen receptor (ER) degrader, known as a proteolysis-targeting chimera (PROTAC ), ...

(EBC) patients receiving Kisqali in 1-year post-treatment analysis1Tolerability remained consistent, with fewer treatment discontinuations due to adverse events among pre-menopausal patients1Rising br ...

Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared ...

Pfizer (PFE) and Arvinas (ARVN) aim to seek FDA approval for thier breast cancer therapy vepdegestrant in H2 2025. Read more ...

The treatment could also delay the need for gruelling chemotherapy, according to the trial. | ITV National News ...

The lead author said the study also showed the inavolisib-based therapy "more than doubled the time before their cancer progressed or worsened".

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive final results from the overall survival (OS) analysis of the Phase III INAVO120 study. These data showed ...

A “breakthrough” new three-drug combination offers hope for women battling an aggressive form of breast cancer, potentially ...

Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients with ...